•
Mar 31, 2021

Ultralife Q1 2021 Earnings Report

Ultralife reported increased year-over-year revenue for the first quarter, driven by Battery & Energy Products, with medical and government/defense sales up, offset by sluggishness in oil & gas and lower Communications Systems sales.

Key Takeaways

Ultralife Corporation reported a slight increase in revenue for Q1 2021, with operating income decreasing compared to the same period last year. The revenue increase was primarily driven by growth in the Battery & Energy Products segment, particularly in medical and government/defense sales, while profitability was affected by start-up costs for new product transitions and investments in engineering and sales resources.

Revenue increased by 0.6% to $26.0 million compared to $25.8 million in Q1 2020.

Battery & Energy Products revenue increased by 6.5%, driven by medical device and government/defense sales.

Communications Systems sales decreased by 23.6% due to completion of vehicle amplifier-adaptor systems orders.

Operating income decreased to $1.0 million from $1.5 million in the previous year.

Total Revenue
$26M
Previous year: $25.8M
+0.6%
EPS
$0.05
Previous year: $0.08
-37.5%
Adjusted EBITDA
$2M
Previous year: $2.5M
-20.0%
Gross Profit
$7M
Previous year: $7.3M
-4.1%
Cash and Equivalents
$13.6M
Previous year: $5.86M
+131.6%
Free Cash Flow
$3.41M
Previous year: -$930K
-467.1%
Total Assets
$136M
Previous year: $146M
-6.7%

Ultralife

Ultralife

Ultralife Revenue by Segment

Revenue & Expenses

Visualization of income flow from segment revenue to net income